NMRA
Neumora Therapeutics, Inc.
Key Financials
Operating Income
$-241156000
↑ 8.5%
Net Income
$-236928000
↑ 2.8%
EPS (Diluted)
$-1.45
↑ 5.2%
Shareholders' Equity
$103.9M
↓ 63.8%
Total Liabilities
$87.2M
↑ 191.5%
Cash & Equivalents
$182.5M
↑ 28.4%
Total Assets
$191.0M
↓ 39.7%
Operating Cash Flow
$-206440000.00
↓ 12.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEFA14A | 4/17/2026 | View on SEC |
| DEF 14A | 4/17/2026 | View on SEC |
| SCHEDULE 13D/A | 4/1/2026 | View on SEC |
| S-8 | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
| 4 | 2/19/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NMRA |
| Company Name | Neumora Therapeutics, Inc. |
| CIK | 1885522 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (857) 760-0900 |